Flagging Patients Boosts Kidney Disease Care
A quality improvement study found that flagging high-risk patients and auditing physicians improved kidney disease testing and treatment.
Updated on Nov. 11, 2026 in Diabetes

Navdeep Tangri and colleagues flagged roughly 3 in 10 chronic kidney disease patients as high risk using laboratory data already in the medical record. Presented at ASN Kidney Week in Denver on October 23, 2026, the study found nearly all physicians improved their urine albumin testing.
Why it matters
Physicians want to give optimal care, but busy practices and clinical inertia can get in the way. The findings suggest simple record-based flags and peer benchmarking can help close that gap in managing chronic kidney disease.
The study reports that about 3 in 10 chronic kidney disease patients were flagged as high risk, and an estimated 80% to 90% of more than 180 physicians increased guideline-directed therapy use. The abstract does not yet show whether these process gains changed patient outcomes.
The players
Navdeep Tangri
Tangri is a nephrologist and researcher at the University of Manitoba in Canada who leads work on kidney disease risk prediction and care delivery.
ASN Kidney Week
ASN Kidney Week is the annual meeting of the American Society of Nephrology, where clinicians and researchers present kidney disease studies.
The details
Researchers tested two strategies: flagging high-risk patients in the medical record and sending physicians quarterly audits and feedback. Physicians were benchmarked on urine albumin-to-creatinine ratio testing against peers in their local clinic, region and the practice overall, and the flags let them plan time and resources before seeing patients.
Timeline
October 23, 2026: Abstract FR-PO0018 presented at ASN Kidney Week in Denver.
November 9, 2026: Abstract made available online.
November 11, 2026: Pharmacy Times published coverage of the study.
Big Picture
The study tests whether practice-level tools can move KDIGO clinical practice guidelines for chronic kidney disease into routine care. Its process gains rest on guideline-directed testing and therapy rather than new drugs.
Patients with chronic kidney disease may be more likely to receive urine albumin testing and guideline-directed therapy if their clinics adopt similar flags. Whether this changes long-term kidney outcomes remains to be shown.
The takeaway
Simple record-based flags and peer benchmarking can help clinics act on existing lab data for kidney disease patients. Clinicians and patients alike may benefit from asking whether high-risk CKD patients are getting timely urine testing and guideline-based treatment.
Further reading
For related context on the disease area, see Diabetes.
More information
Read the full Kidney Week 2026 abstract FR-PO0018 from the American Society of Nephrology.
Source note: This article includes information reported by Pharmacytimes.



